What Bioprofarma Bagó does

Bioprofarma Bagó (legal name: Laboratorios Bioprofarma Bagó S.A.) is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, headquartered at Terrada 1270, Buenos Aires. Founded in 2003, the company develops, manufactures, and commercializes high-complexity prescription medications targeting five therapeutic verticals: hematology (Benzimir), oncology (Anastradex), special treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), urology (a portfolio of ten products including Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and rare diseases (Eibanta, Gaust). Its core technology is specialized pharmaceutical manufacturing for elevated-complexity pathologies, with proprietary formulations across urology-oncology (enzalutamide, abiraterone acetate, apalutamide, bicalutamide), rare-disease therapeutics (icatibanto, miglustat, sulthiame, edaravone), and oncology APIs (anastrozole). The 2026 acquisition of Eriochem added a wholly owned Argentine oncology laboratory in Entre Ríos.

The company operates a B2B/B2C sales-led GTM motion distributing prescription medications through healthcare institutions, hospitals, and pharmacies under ANMAT regulatory oversight in 28 countries spanning Latin America, Asia-Pacific (including Philippines, Georgia, Mongolia, Myanmar, Vietnam, Thailand, Pakistan, Sri Lanka), and EMEA (Iraq, Lebanon). Revenue mechanics are prescription-driven one-time product sales of high-value-added medications, with the PRIORIDAR patient support program providing adherence, follow-up, and lifestyle services to patients and families. The company employs between 51 and 100 staff (described internally as 'over 80 young collaborators') and is privately held under the Grupo Bagó umbrella, alongside the Biogénesis Bagó animal-health subsidiary that has executed complementary acquisitions of Mayors (Argentina, 2022) and Mundo Animal (Brazil, 2025).

Name

Bioprofarma Bagó

Legal name

Laboratorios Bioprofarma Bagó

Website

https://bioprofarma-bago.com.ar

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

51–100 employees

Short description

Bioprofarma Bagó is the specialty pharmaceutical division of Argentine conglomerate Grupo Bagó, developing, manufacturing, and commercializing high-complexity prescription medications across hematology, oncology, urology, special treatments, and rare diseases for patients in 28 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Oncology medications
• Hematology treatments
• Rare disease drugs
• Patient support programs

Headquarters

HQ city

Buenos Aires

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Sale of high-value-added medications for the treatment of complex diseases including hematological, oncological, urological conditions, special treatments, and rare diseases

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Bioprofarma Bagó develops, manufactures, and commercializes high-complexity prescription medications for the treatment of hematological, oncological, and urological conditions, special treatments, and rare diseases. The portfolio includes specialty drugs such as Benzimir (hematology), Anastradex (oncology), Hutus and Androstat (prostate cancer), and Eibanta (hereditary angioedema), distributed through healthcare institutions, hospitals, and pharmacies across Latin America, Asia, the Middle East, and Eastern Europe.

Product overview

Bioprofarma Bagó is a pharmaceutical division of the Argentine Bagó group that develops, produces, and commercializes high-complexity medications. The portfolio consists of five therapeutic categories: Hematology (Benzimir), Oncology (Anastradex), Special Treatments (Actiluzol, Antixan, Eibanta, Gaust, Kalisma, Ragnerol), Urology (Androstat, Bidrostat, CarciVac, Flutrax, Hutus, Kestava, Mitotie, Paknira, Sinresor, UroControl, Urodif Dúo), and Rare Diseases (Eibanta, Gaust). The company also provides patient support through the PRIORIDAR program. Products target hematological, oncological, urological conditions, special treatments, and rare diseases, with a global presence across Latin America and select international markets including Philippines, Georgia, Myanmar, Vietnam, Thailand, Pakistan, Iraq, and Lebanon.

Differentiator

Problem solved

Functional benefit

Brands

• PRIORIDAR: Patient support program providing information, treatment follow-up, and support services for patients and families during treatment.

Products and services

• Benzimir Hematology medication produced by Bioprofarma Bagó for the treatment of hematological conditions.
• Anastradex Oncology medication for cancer treatment produced by Bioprofarma Bagó.
• Actiluzol Special treatment medication containing riluzole for neurological conditions.
• Hutus Urology medication containing enzalutamide for prostate cancer treatment.
• Eibanta Treatment for acute attacks of hereditary angioedema, presented as a pre-filled syringe with 30mg icatibanto and 25G hypodermic needle.
• Antixan Special treatment containing edaravone for neurological conditions.
• Gaust Special treatment containing miglustat for rare diseases.
• Kalisma Special treatment containing sulthiame.
• Ragnerol Special treatment containing caspofungin for antifungal therapy.
• Androstat Urology medication containing cyproterone acetate for prostate cancer treatment, presented as 50mg x 50 tablets.
• Bidrostat Urology medication containing bicalutamide for prostate cancer.
• CarciVac Urology medication containing Onco BCG (Bacillus Calmette-Guérin) for bladder cancer treatment.
• Flutrax Urology medication containing flutamide for prostate cancer.
• Kestava Urology medication containing abiraterone acetate for prostate cancer.
• Mitotie Urology medication containing mitomycin for cancer treatment.
• Paknira Urology medication containing apalutamide for prostate cancer.
• Sinresor Urology medication containing zoledronic acid.
• UroControl Urology diagnostic product for liquid biopsy in urine testing.
• Urodif Dúo Urology medication combining dutasteride and tamsulosin hydrochloride.
• PRIORIDAR Patient Program Patient support program providing information, treatment follow-up, and healthy lifestyle guidance for patients and families undergoing treatment with Bioprofarma Bagó medications.

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Mundo Animal (Brazil)coreStrategic or Co-development Partner · 1 January 2025Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) in January 2025 to expand into the pet care market in Brazil, complementing the Mayors acquisition and strengthening the group's Latin American pet health positioning.
• Mayors (Argentina)coreStrategic or Co-development Partner · 1 January 2022Acquired by Biogenesis Bagó (animal health subsidiary of the Bagó group) to expand into the pet care market in Argentina as part of the group's pet health strategy.
• EriochemcoreStrategic or Co-development PartnerBioprofarma Bagó acquired 100% of Eriochem, an Argentine laboratory specializing in oncology medications based in Entre Rios. This acquisition enables synergies in research, production, and commercialization aligned with Bioprofarma Bago's high-impact therapeutic strategy, strengthening their oncology portfolio.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Teva Pharmaceutical Industries: Global specialty and generics leader with strong LATAM and emerging market presence. Comparable as a large-scale competitor offering both specialty and generic versions of many molecules Bioprofarma distributes.
• Laboratorios Bagó: Parent group of Bioprofarma Bagó and one of the largest Argentine pharmaceutical companies. Operates broadly across multiple therapeutic areas including animal health (Biogénesis Bagó); provides the corporate and distribution backbone for Bioprofarma's specialty division.
• Astellas Pharma: Global originator of enzalutamide (Xtandi), directly competing with Bioprofarma's Hutus in prostate cancer. Representative of the multinational originator competition Bioprofarma faces in urology oncology.

Direct peers

• Laboratorios Roemmers: Leading Argentine pharmaceutical company with a broad branded specialty and primary care portfolio across Latin America. Comparable as a fellow Argentine pharma with multi-country LATAM distribution and similar therapeutic breadth.
• Eriochem: Argentine oncology-focused laboratory recently acquired by Bioprofarma Bagó. Specializes in oncology medications for high-complexity treatments, making it the closest direct comparator on therapeutic focus and geography.
• Gador: Argentine pharmaceutical company with strong specialty and oncology presence across LATAM. Directly comparable therapeutic categories (oncology, specialty care) and similar regional distribution model.
• Laboratorios Raffo: Argentine specialty pharmaceutical company with branded generics and specialty products across oncology and complex therapies. Comparable as a mid-sized Argentine pharma competing in similar therapeutic niches.
• Elea Phoenix: Argentine pharmaceutical group (formed by merger of Elea and Phoenix) with branded specialty products across LATAM. Comparable in scale, therapeutic breadth, and Argentine-headquartered specialty pharma positioning.

Regional players

• Laboratorio Chile (Teva affiliate): Major LATAM specialty/generics player with strong presence in Chile and broader Andean/Pacific Alliance markets where Bioprofarma also competes in oncology and specialty therapeutics.

Others

• Biogénesis Bagó: Animal-health subsidiary of the same Bagó Group, with 200+ pet health SKUs and top-10 LATAM ranking. Sister company rather than direct competitor; included as ecosystem context for the parent group's broader pharmaceutical platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/bioprofarma-bagó-s-a

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioprofarma Bagó